Worth reading
35Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.Agreements reached under this partnership
Joint research agreement4882Perseus Proteomics Inc.
Alliance partnerEurus Therapeutics Co., Ltd.
About the partner
Business DescriptionDevelopment of novel gene therapies
LocationFujisawa, Kanagawa
Impact on Business Performance
The impact of this agreement on the Company's results of operations at present is minor.
| Item | Details |
|---|---|
| Name of alliance partner | Eurus Therapeutics Co., Ltd. |
| Alliance partner's business activities | Development of novel gene therapies |
| Alliance partner's location | Fujisawa, Kanagawa |
| Type of alliance | Joint research agreement |
| Impact on Business Performance | The impact of this agreement on the Company's results of operations at present is minor. |
Items this document does not state (18)
Alliance partner's capitalAlliance partner's net salesAlliance partner's operating incomeDetails of the allianceNumber of shares acquiredAcquisition priceShareholding ratioOverview of the joint ventureOwnership ratioDispatch of directors and officersContract PeriodNumerical targets under the allianceShareholding PolicyDate of board resolutionContract DateAlliance start dateShare Acquisition Date and Payment DateChange in major shareholders
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The parties confirmed results in their previous joint research that would lead to further progress in obtaining the target antibodies and antibody genes. The parties aim to create novel therapeutics by leveraging the synergies between PPMX Antibody Library 2 and Eurus's novel genome-editing technology.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.